BAKER BROS. ADVISORS LP
Q3 2022 13F-HR Holdings
Net value change ($000)
-2,357,541
(-13.4%)
New positions
12
Sold out positions
13
Turnover %
1.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Global Blood Therapeutics, Inc. | 134,930 | 113.1% |
| RYTM | 131,417 | 767.7% |
| ACAD | 95,166 | 16.1% |
| AKRO | 79,524 | 7106.7% |
| ASND | 49,982 | 11.1% |
| ChemoCentryx, Inc. | 48,187 | 108.5% |
| Verve Therapeutics, Inc. | 27,013 | 124.8% |
| CinCor Pharma, Inc. | 26,493 | NEW |
| BCRX | 25,676 | 19.1% |
| IDYA | 24,892 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Seagen Inc. | -1,881,651 | -22.7% |
| INCY | -337,287 | -12.3% |
| ARGX | -325,268 | -76.7% |
| ONC | -315,410 | -16.7% |
| LEGN | -47,116 | -100.0% |
| INSM | -42,086 | -99.0% |
| Horizon Therapeutics Public Ltd Co | -31,589 | -34.5% |
| CERS | -27,154 | -31.9% |
| ALKERMES PLC | -26,486 | -59.3% |
| AMARIN CORP PLC | -25,682 | -81.4% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|